The synergistic effect of LBH589, a histone deacetylase inhibitor, and 17AAG downregulated p-Flt3, p-Akt, p-ERK1/2, and BCR-ABL levels in CML cells [77]. This evidence concerns the gene MAPK3 and chronic myelogenous leukemia, BCR-ABL1 positive.